basically needs 1 think to be re-rated and that is for a big pharma to come in and fund further trials.
the single biggest factor between the 'have' and 'have nots' is funding. without a backer, you have dilution.
i'm sure management would be in discussions with a number of pharmas given recent results will have gained the intention of these groups
share price is a disgrace, page-6
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
-0.001(3.70%) |
Mkt cap ! $23.45M | |||
| Open | High | Low | Value | Volume |
| 2.8¢ | 2.8¢ | 2.6¢ | $8.096K | 297.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 121152 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| BIT (ASX) Chart |